Table 1.
ESR1 mutation rate reported in selected metastatic breast cancer trials.
| Sample Studies | Patients (n Substudy/Total n on Trial) |
Comparator Trial Arms | Prevalence of ESR1 Mutations |
|---|---|---|---|
| BOLERO-2 (NCT00863655) | 541/724 | Exemestane + everolimus vs. exemestane | 28.8% |
| SOFeA (NCT00253422) | 161/723 | Fulvestrant + anastrozole vs. fulvestrant | 39% |
| PALOMA-3 (NCT01942135) | 195/521 | Palbociclib + fulvestrant vs. fulvestrant | 25.3% |
| MONALEESA-2 (NCT01958021) | 494/668 | Ribociclib + letrozole vs. letrozole | 4% |
| FERGI (NCT01437566) | 153/168 | Pictilisib + fulvestrant vs. fulvestrant | 37% |